´ëÇÑ°áÇÙ ¹× È£Èí±âÇÐȸ¿Í ±¹Á¦°áÇÙ¿¬±¸¼¾ÅÍ¿¡¼ °øµ¿ÁÖ°üÇÏ´Â Á¦ 2ȸ ´ÙÁ¦
³»¼º°áÇÙ ±Øº¹À» À§ÇÑ ±¹Á¦½ÉÆ÷Áö¾öÀÌ ¿¸³´Ï´Ù.
ÀϽÃ: 2006³â 11¿ù 9ÀÏ 1½Ã
Àå¼Ò: ¼¿ï Àá½Ç·Ôµ¥È£ÅÚ
¸¹Àº Âü¿©¸¦ ºÎŹµå¸³´Ï´Ù.
Dr. Douglas young, Department of Infectious Diseases and
Microbiology, Centre for Molecular Microbiology and Infection,
Imperial College London
"Drugs for Latent TB: A Grand Challenge in Global Health"
Dr. Ken Duncan, Bill & Melinda Gates Foundation
"The future of TB drug discovery"
Dr. Clifton E. Barry III, Tuberculosis research section, National
Institute of Allergy and Infectious Disease, NIH
"The potential of nitroimidazoles to alter the duration of
chemotherapy for TB"
Dr. Thomas Dick, Novartis Institute of Tropical Diseases, Singapore
"Update on TB drug discovery at NITD"
Dr. Joanne Flynn, Department of Molecular Genetics and Biochemistry,
University of Pittsburgh School of Medicine
"Non-human primate model of tuberculosis: What can we learn?"
Dr. Laura E. Via, Tuberculosis research section,, National Institute
of Allergy and Infectious Disease, NIH
"Hypoxic Microenvironments in Animal Models of Tuberculosis"
Dr. Ma. de Lourdes Garcia-Garcia, National Institute of Public
Health, Mexico:
"Molecular epidemiology of tuberculosis in Southeastern Mexico"
|
|